Monday, 20 August 2012

Solid Tumors Medications


Drugs associated with Solid Tumors

The following drugs and medications are in some way related to, or used in the treatment of Solid Tumors. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.





Drug List:

Tuesday, 14 August 2012

Cortomycin





Dosage Form: ear drops
Neomycin and Polymyxin B Sulfates

and Hydrocortisone

Description


Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Solution USP is a sterile antibacterial and anti-inflammatory solution for otic use.


Each mL Contains: ACTIVES: Neomycin Sulfate equivalent to 3.5 mg neomycin base, Polymyxin B Sulfate equivalent to 10,000 polymyxin B units, Hydrocortisone 10 mg (1%). INACTIVES: Propylene Glycol, Hydrochloric Acid, Potassium Metabisulfite, Cupric Sulfate, Glycerin, Purified Water. The pH range is 2.0 to 4.5.


Neomycin Sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 micrograms of neomycin standard per milligram, calculated on an anhydrous basis. The structural formulae are:



Polymyxin b Sulfate is the sulfate salt of polymyxin B1 and B2 which are produced by the growth of bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per milligram, calculated on an anhydrous basis. The structural formulae are:



Hydrocortisone, 11β, 17, 21 - trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is:



C21H30O5 Mol. Wt. 362.47



Clinical Pharmacology


Corticoids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body’s defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.


The anti-infective components in the combination are included to provide action against specific organisms susceptible to them. Neomycin sulfate and polymyxin B sulfate together are considered active against the following microorganisms: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae.


The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.



Indications and Usage


For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics.



Contraindications


This product is contraindicated in those individuals who have shown hypersensitivity to any of its components. This product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous viral infection (for example, herpes simplex virus or varicella zoster virus).



Warnings


Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk of ototoxicity is greater with prolonged use; therefore, duration of therapy should be limited to 10 consecutive days (see PRECAUTIONS: General).


Patients being treated with eardrops containing neomycin should be under close clinical observation. Due to its acidity which may cause burning and stinging, neomycin and polymyxin B sulfates and hydrocortisone otic solution should not be used in any patients with a perforated tympanic membrane.


Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. Discontinue this product promptly if sensitization or irritation occurs.


When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for the patient thereafter.


Contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.



Precautions



General


As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.


If the infection is not improved after 1 week, cultures and susceptibility tests should be repeated to verify the identity of the organism and to determine whether therapy should be changed.


Treatment should not be continued for longer than 10 days.


Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin; paromomycin; streptomycin; and possibly, gentamicin.



Information for patients


Avoid contaminating bottle tip with material from the ear, fingers or other source. This caution is necessary if the sterility of the drops is to be preserved.


If sensitization or irritation occurs, discontinue use immediately and contact your physician.


Do not use in the eyes.



Laboratory tests


Systemic effects of excessive levels of hydrocortisone may include a reduction in the number of circulating eosinophils and a decrease in urinary excretion of 17-hydroxycorticosteroids.



Carcinogenesis, mutagenesis, impairment of fertility


Long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity attributable to oral administration of corticosteroids.



Pregnancy


Teratogenic effects

Pregnancy Category C: Corticosteroids have been shown to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



Nursing mothers


Hydrocortisone appears in human milk following oral administration of the drug. Since systemic absorption of hydrocortisone may occur when applied topically, caution should be exercised when neomycin and polymyxin B sulfates and hydrocortisone otic solution is used by a nursing woman.



Pediatric use


The safety and effectiveness of neomycin and polymyxin B sulfates and hydrocortisone otic solution in otitis externa have been established in the pediatric age group 2 years to 16 years of age. There is inadequate data to establish safety and effectiveness in otitis externa for pediatric patients under 2 years of age 1.



1


Jones, RN, Milazzo J, Seidlin, M. Ofloxacin Otic Solution for Treatment of Otitis Externa in Children and Adults. Arch Otolaryngol Head Neck Surg. 1997; 123; 1193-1200.




Geriatric use


Clinical studies of neomycin and polymyxin B sulfates and hydrocortisone otic solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.



Adverse Reactions


Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%.3


The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear.



2


Leyden JJ. Kligman AM. Contact dermatitis to neomycin sulfate. JAMA 1979; 242: 276-1278.



3


Prystowsky SD, Allen AM, Smith RW, Nonomura JH, Odum RB, Akers WA. Allergic contact hypersensitivity to nickel, neomycin, ethylenediamine, and benzocaine: relationships between age, sex, history of exposure, and reactivity to standard patch tests and use tests in general population. Arch Dermatol 1979; 115:959-962.




Dosage and Administration


Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator.


For adults, four drops of the solution should be instilled into the affected ear 3 or 4 times daily. For infants and children, three drops are suggested because of the smaller capacity of the ear canal.


The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear.


If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the solution. This wick should be kept moist by adding further solution every 4 hours. The wick should be replaced at least once every 24 hours.



How Supplied


Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Solution USP is supplied in a white plastic dropper bottle in the following size:


10 mL - Prod. No. 10009


STERILE OTIC SOLUTION


Rx only


FOR USE IN THE EARS ONLY


NOT FOR USE IN THE EYES



Storage


Store between 15°-30°C (59°- 86°F).


Securely tighten cap between uses.


DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT



Manufacturer Information


Bausch & Lomb Incorporated


Tampa, FL 33637

©Bausch & Lomb Incorporated


Revised February 2008


9072201 (Folded)

9072101 (Flat)

Prod. No. 10009



Principle Display Panel











Cortomycin 
neomycin and polymyxin b sulfates and hydrocortisone  solution/ drops










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0904-3141 (0904-3141)
Route of AdministrationOPHTHALMICDEA Schedule    














Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
NEOMYCIN SULFATE (NEOMYCIN)NEOMYCIN SULFATE3.5 mg  in 1 mL
POLYMYXIN B SULFATE (POLYMYXIN B)POLYMYXIN B SULFATE10000 [USP'U]  in 1 mL
HYDROCORTISONE (HYDROCORTISONE)HYDROCORTISONE10 mg  in 1 mL





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
10904-3141-101 BOTTLE In 1 CARTONcontains a BOTTLE, DROPPER
110 mL In 1 BOTTLE, DROPPERThis package is contained within the CARTON (0904-3141-10)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA06405306/01/2004


Labeler - Major Pharmaceuticals (191427277)
Revised: 10/2009Major Pharmaceuticals

More Cortomycin resources


  • Cortomycin Use in Pregnancy & Breastfeeding
  • Cortomycin Drug Interactions
  • Cortomycin Support Group
  • 0 Reviews for Cortomycin - Add your own review/rating


  • Cortomycin Concise Consumer Information (Cerner Multum)

  • Cortomycin Advanced Consumer (Micromedex) - Includes Dosage Information

  • Cortomycin Solution MedFacts Consumer Leaflet (Wolters Kluwer)

  • AK-Spore HC Otic Suspension Concise Consumer Information (Cerner Multum)



Compare Cortomycin with other medications


  • Blepharitis
  • Conjunctivitis, Bacterial
  • Keratitis
  • Keratoconjunctivitis
  • Uveitis

Prednisolone/Sulfacetamide Ointment


Pronunciation: pred-NISS-oh-lone/sul-fa-SEE-ta-mide
Generic Name: Prednisolone/Sulfacetamide
Brand Name: Blephamide S.O.P.


Prednisolone/Sulfacetamide Ointment is used for:

Treating inflammation (swelling, warmth, redness, pain) of the eyes and eyelids when infection or risk of infection is present.


Prednisolone/Sulfacetamide Ointment is an antibacterial and corticosteroid combination. It works by reducing the itching, redness, and swelling of the eye. It also works to stop the growth of certain bacteria that cause eye infections.


Do NOT use Prednisolone/Sulfacetamide Ointment if:


  • you are allergic to any ingredient in Prednisolone/Sulfacetamide Ointment, to other corticosteroids (eg, dexamethasone), or to other sulfonamides (eg, acetazolamide, celecoxib, hydrochlorothiazide, glyburide, probenecid, sulfamethoxazole, valdecoxib, zonisamide)

  • you have a viral eye infection (eg, herpes simplex, vaccinia, chickenpox), tuberculosis eye infection, or fungal infection of the eye or eye structures

  • you have thinning of the cornea of the eye

Contact your doctor or health care provider right away if any of these apply to you.



Before using Prednisolone/Sulfacetamide Ointment:


Some medical conditions may interact with Prednisolone/Sulfacetamide Ointment. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have thinning of the eye tissues (eg, cornea, sclera), other eye problems (eg, glaucoma, cataracts, nerve damage), severe dry eyes, or diabetes

  • if you have recently had cataract surgery

Some MEDICINES MAY INTERACT with Prednisolone/Sulfacetamide Ointment. Tell your health care provider if you are taking any other medicine, especially any of the following:


  • Silver-containing medicines (eg, silver nitrate) because the risk of side effects may be increased

This may not be a complete list of all interactions that may occur. Ask your health care provider if Prednisolone/Sulfacetamide Ointment may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Prednisolone/Sulfacetamide Ointment:


Use Prednisolone/Sulfacetamide Ointment as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Prednisolone/Sulfacetamide Ointment may be used around the eye or in the eye. To use Prednisolone/Sulfacetamide Ointment in the eye, first, wash your hands. Using your index finger, pull the lower eyelid away from your eye to form a pouch. Squeeze a thin strip of ointment into the pouch. After using Prednisolone/Sulfacetamide Ointment, gently close your eyes for 1 to 2 minutes. Wash your hands to remove any medicine that may be on them. Wipe the applicator tip with a clean, dry tissue.

  • To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.

  • To clear up your infection completely, use Prednisolone/Sulfacetamide Ointment for the full course of treatment. Keep using it even if you feel better in a few days.

  • Do not use Prednisolone/Sulfacetamide Ointment if it is dark brown or has darkened since you began using it. Contact your doctor or pharmacist if you have questions about whether you should use Prednisolone/Sulfacetamide Ointment.

  • Do not wear contact lenses while you are using Prednisolone/Sulfacetamide Ointment. Take care of your contact lenses as directed by the manufacturer. Check with your doctor before you use them.

  • If you miss a dose of Prednisolone/Sulfacetamide Ointment, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Prednisolone/Sulfacetamide Ointment.



Important safety information:


  • Prednisolone/Sulfacetamide Ointment may cause blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Prednisolone/Sulfacetamide Ointment with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • If your symptoms do not get better within 2 days or if they get worse, check with your doctor.

  • Be sure to use Prednisolone/Sulfacetamide Ointment for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.

  • Long-term or repeated use of Prednisolone/Sulfacetamide Ointment may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.

  • Tell your doctor or dentist that you take Prednisolone/Sulfacetamide Ointment before you receive any medical or dental care, emergency care, or surgery.

  • Do not use Prednisolone/Sulfacetamide Ointment for future eye problems unless directed by your doctor.

  • Lab tests, including eye pressure, may be performed while you use Prednisolone/Sulfacetamide Ointment. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Prednisolone/Sulfacetamide Ointment should be used with extreme caution in CHILDREN younger than 6 years old; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Prednisolone/Sulfacetamide Ointment while you are pregnant. It is not known if Prednisolone/Sulfacetamide Ointment is found in breast milk. Do not breast-feed while using Prednisolone/Sulfacetamide Ointment.


Possible side effects of Prednisolone/Sulfacetamide Ointment:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Temporary burning or stinging.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); changes in vision; eye pain, itching, redness, swelling, irritation, or sores not present when you began using Prednisolone/Sulfacetamide Ointment; fever, chills, or sore throat; red, swollen, or blistered skin; severe or persistent blurred vision; unusual tiredness or weakness; yellowing of the eyes or skin.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Prednisolone/Sulfacetamide side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Prednisolone/Sulfacetamide Ointment:

Store Prednisolone/Sulfacetamide Ointment at room temperature, between 59 and 77 degrees F (15 and 25 degrees C). Do not freeze. Store away from heat and light. Keep Prednisolone/Sulfacetamide Ointment out of the reach of children and away from pets.


General information:


  • If you have any questions about Prednisolone/Sulfacetamide Ointment, please talk with your doctor, pharmacist, or other health care provider.

  • Prednisolone/Sulfacetamide Ointment is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Prednisolone/Sulfacetamide Ointment. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Prednisolone/Sulfacetamide resources


  • Prednisolone/Sulfacetamide Side Effects (in more detail)
  • Prednisolone/Sulfacetamide Dosage
  • Prednisolone/Sulfacetamide Use in Pregnancy & Breastfeeding
  • Prednisolone/Sulfacetamide Drug Interactions
  • Prednisolone/Sulfacetamide Support Group
  • 1 Review for Prednisolone/Sulfacetamide - Add your own review/rating


Compare Prednisolone/Sulfacetamide with other medications


  • Blepharitis
  • Conjunctivitis, Bacterial
  • Keratitis
  • Keratoconjunctivitis
  • Uveitis

Saturday, 11 August 2012

altretamine


Generic Name: altretamine (all TREH tah mean)

Brand Names: Hexalen


What is altretamine?

Altretamine is a cancer (antineoplastic) medication. Altretamine interferes with the growth of cancer cells and slows their growth and spread in the body.


Altretamine is used to treat cancer of the ovaries.


Altretamine may also be used for purposes other than those listed in this medication guide.


What is the most important information I should know about altretamine?


Altretamine should only be administered under the supervision of a qualified healthcare provider experienced in the use of cancer chemotherapeutic agents.


Serious side effects have been reported with the use of altretamine including: allergic reactions (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; fever or chills; or signs of infection such as fever; chills, or sore throat); neurologic problems (mood disorders, altered consciousness, weakness, dizziness, vertigo); and others. Talk to your doctor about the possible side effects from treatment with altretamine.


What should I discuss with my healthcare provider before taking altretamine?


Before taking altretamine, tell your doctor if you have:



  • any nervous system (brain and nerves) problems; or




  • bone marrow problems.



You may not be able to take altretamine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.


Altretamine is in the FDA pregnancy category D. This means that altretamine is known to cause birth defects in an unborn baby. Do not take altretamine without first talking to your doctor if you are pregnant or could become pregnant during treatment. Contraceptive measures are recommended during treatment with altretamine. It is not known whether altretamine passes into breast milk. Do not take altretamine without first talking to your doctor if you are breast feeding a baby.

How should I take altretamine?


Take altretamine exactly as directed by your doctor. If you do not understand these instructions, as your doctor, nurse or pharmacist to explain them to you.


Your doctor will determine the correct amount and frequency of treatment with altretamine depending upon the cancer being treated and other factors. Talk to your doctor if you have any questions or concerns regarding the treatment schedule.


Altretamine is usually taken four times a day, after meals and at bedtime.


Take each oral dose with a large glass of water.

Your doctor will probably want you to have regularly scheduled blood tests and other medical evaluations during treatment with altretamine to monitor progress and side effects.


Store altretamine capsules at room temperature away from heat and moisture. Keep this product out of the reach of children.

See also: Altretamine dosage (in more detail)

What happens if I miss a dose?


Contact your doctor if you miss a dose of altretamine.


What happens if I overdose?


If for any reason an overdose of altretamine is suspected, seek emergency medical attention or contact your healthcare provider immediately.

Symptoms of an altretamine overdose tend to be similar to side effects caused by the medication, although often more severe.


What should I avoid while taking altretamine?


Altretamine can lower the activity of your immune system making you susceptible to infections. Avoid contact with people who have colds, the flu, or other contagious illnesses and do not receive vaccines that contain live strains of a virus (e.g., live oral polio vaccine) during treatment with altretamine. In addition, avoid contact with individuals who have recently been vaccinated with a live vaccine. There is a chance that the virus can be passed on to you.


Altretamine side effects


If you experience any of the following serious side effects, seek emergency medical attention or contact your doctor immediately:

  • an allergic reaction (shortness of breath; closing of your throat; difficulty breathing; swelling of your lips, face, or tongue; or hives);




  • decreased bone marrow function and blood problems (extreme fatigue; easy bruising or bleeding; black, bloody or tarry stools; or fever, chills, or signs of infection);




  • pain, tremors, tingling, burning, or prickling in hands or feet;




  • mood changes;




  • severe drowsiness or loss of consciousness;




  • loss of coordination, weakness, dizziness, unsteadiness or falling; or




  • severe nausea or vomiting.



Other less serious side effects may be more likely to occur. Talk to your doctor if you experience:



  • temporary hair loss;




  • itching or rash; or




  • mild to moderate nausea or vomiting.



Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.


Altretamine Dosing Information


Usual Adult Dose for Ovarian Cancer:

260 mg/m2/day administered either for 14 or 21 consecutive days in a 28 day cycle. The total daily dose should be given as 4 divided oral doses after meals and at bedtime.

Altretamine should be temporarily discontinued (for 14 days or longer) and subsequently restarted at 200 mg/m2/day for any of the following situations:

Gastrointestinal intolerance unresponsive to symptomatic measures;
White blood count Platelet count Progressive neurotoxicity.

If neurologic symptoms fail to stabilize on the reduced dose schedule, altretamine should be discontinued indefinitely.


What other drugs will affect altretamine?


Before taking altretamine, tell your doctor if you are taking a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate). You may require a dosage adjustment or special monitoring during treatment if you are taking one of these medicines.


Before taking altretamine, tell your doctor if you are taking cimetidine (Tagamet, Tagamet HB). You may require a dosage adjustment or special monitoring during treatment.


Do not receive "live" vaccines during treatment with altretamine. Administration of a live vaccine may be dangerous during treatment with altretamine.

Drugs other than those listed here may also interact with altretamine. Talk to your doctor and pharmacist before taking any other prescription or over-the-counter medicines, including herbal products, during treatment with altretamine.



More altretamine resources


  • Altretamine Side Effects (in more detail)
  • Altretamine Dosage
  • Altretamine Use in Pregnancy & Breastfeeding
  • Altretamine Drug Interactions
  • Altretamine Support Group
  • 0 Reviews for Altretamine - Add your own review/rating


  • altretamine Advanced Consumer (Micromedex) - Includes Dosage Information

  • Altretamine Professional Patient Advice (Wolters Kluwer)

  • Altretamine Monograph (AHFS DI)

  • Altretamine MedFacts Consumer Leaflet (Wolters Kluwer)

  • Hexalen Prescribing Information (FDA)



Compare altretamine with other medications


  • Ovarian Cancer


Where can I get more information?


  • Your pharmacist has additional information about altretamine written for health professionals that you may read.

See also: altretamine side effects (in more detail)


Thursday, 9 August 2012

Septrin Tablets 80 mg / 400 mg





1. Name Of The Medicinal Product



Septrin 80 mg/400 mg Tablets


2. Qualitative And Quantitative Composition



Each tablet contains 400 mg Sulfamethoxazole and 80 mg Trimethoprim



Excipients,



For a full list of excipients, see Section 6.1



3. Pharmaceutical Form



Tablets.



White, biconvex tablets marked “GX Y2B” with scoreline on one side.



4. Clinical Particulars



4.1 Therapeutic Indications



Septrin tablets are indicated for the treatment of the following infections when owing to sensitive organisms (see section 5.1):



Treatment and prevention of Pneumocystis jiroveci (P. carinii) pneumonitis



Treatment and prophylaxis of toxoplasmosis



Treatment of nocardiosis



The following infections may be treated with Septrin where there is bacterial evidence of sensitivity to Septrin and good reason to prefer the combination of antibiotics in Septrin to a single antibiotic:



Acute uncomplicated urinary tract infection



Acute otitis media



Acute exacerbation of chronic bronchitis



Consideration should be given to official guidance on the appropriate use of antibacterial agents.



4.2 Posology And Method Of Administration



Method of administration: oral



It may be preferable to take Septrin with some food or drink to minimise the possibility of gastrointestinal disturbances.



Standard dosage recommendations for acute infections



Adults and children over 12 years:






Tablets




2 every 12 hours



This dosage approximates to 6 mg trimethoprim and 30 mg sulfamethoxazole per kilogram body weight per 24 hours.



Treatment should be continued until the patient has been symptom free for two days; the majority will require treatment for at least 5 days. If clinical improvement is not evident after 7 days' therapy, the patient should be reassessed.



As an alternative to Standard Dosage for acute uncomplicated lower urinary tract infections, short-term therapy of 1 to 3 days' duration has been shown to be effective.



The elderly:



See Special Warnings and Precautions for Use. Unless otherwise specified standard dosage applies.



Impaired hepatic function:



No data are available relating to dosage in patients with impaired hepatic function.



Special Dosage Recommendations



(Standard dosage applies unless otherwise specified)



Where dosage is expressed as "tablets" this refers to the adult tablet, i.e. 80 mg Trimethoprim BP and 400 mg Sulfamethoxazole BP. If other formulations are to be used appropriate adjustment should be made.



Impaired renal function:



Adults and children over 12 years (no information is available for children under 12 years of age):












Creatinine Clearance (ml/min)




Recommended Dosage




>30




STANDARD DOSAGE




15 to 30




Half the STANDARD DOSAGE




<15




Not recommended



Measurements of plasma concentration of sulfamethoxazole at intervals of 2 to 3 days are recommended in samples obtained 12 hours after administration of Septrin. If the concentration of total sulfamethoxazole exceeds 150 microgram/ml then treatment should be interrupted until the value falls below 120 microgram/ml.



Pneumocystis jiroveci (P.carinii) pneumonitis:



Treatment: A higher dosage is recommended, using 20 mg trimethoprim and 100 mg sulfamethoxazole per kg of body weight per day in two or more divided doses for two weeks. The aim is to obtain peak plasma or serum levels of trimethoprim of greater than or equal to 5 microgram/ml (verified in patients receiving 1-hour infusions of intravenous Septrin). (See 4.8 Undesirable Effects).



Prevention:



Adults: The following dose schedules may be used:



160 mg trimethoprim/800 mg sulfamethoxazole daily 7 days per week.



160 mg trimethoprim/800 mg sulfamethoxazole three times per week on alternate days.



320 mg trimethoprim/1600 mg sulfamethoxazole per day in two divided doses three times per week on alternate days.



Children:



The following dose schedules may be used for the duration of the period at risk (see Standard dosage recommendations for acute infections subsection of 4.2):



− Standard dosage taken in two divided doses, seven days per week



− Standard dosage taken in two divided doses, three times per week on alternate days



− Standard dosage taken in two divided doses, three times per week on consecutive days



− Standard dosage taken as a single dose, three times per week on consecutive days



The daily dose given on a treatment day approximates to 150 mg trimethoprim/m2/day and 750 mg sulfamethoxazole/m2/day. The total daily dose should not exceed 320 mg trimethoprim and 1600 mg sulfamethoxazole.



Nocardiosis: There is no consensus on the most appropriate dosage. Adult doses of 6 to 8 tablets daily for up to 3 months have been used.



Toxoplasmosis: There is no consensus on the most appropriate dosage for the treatment or prophylaxis of this condition. The decision should be based on clinical experience. For prophylaxis, however, the dosages suggested for prevention of Pneumocystis jiroveci pneumonitis may be appropriate.



4.3 Contraindications



Septrin should not be given to patients with a history of hypersensitivity to sulphonamides, trimethoprim, co-trimoxazole or any excipients of Septrin.



Contra-indicated in patients showing marked liver parenchymal damage.



Contra-indicated in severe renal insufficiency where repeated measurements of the plasma concentration cannot be performed.



Septrin should not be given to premature babies nor to full-term infants during the first 6 weeks of life except for the treatment/prophylaxis of PCP in infants 4 weeks of age or greater.



4.4 Special Warnings And Precautions For Use



Fatalities, although very rare, have occurred due to severe reactions including Stevens-Johnson syndrome, Lyell's syndrome (toxic epidermal necrolysis), fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, other blood dyscrasias and hypersensitivity of the respiratory tract.



Septrin should be discontinued at the first appearance of skin rash.(see 4.8 Undesirable Effects).



Particular care is always advisable when treating elderly patients because, as a group, they are more susceptible to adverse reactions and more likely to suffer serious effects as a result particularly when complicating conditions exist, e.g. impaired kidney and/or liver function and/or concomitant use of other drugs.



An adequate urinary output should be maintained at all times. Evidence of crystalluria in vivo is rare, although sulphonamide crystals have been noted in cooled urine from treated patients. In patients suffering from malnutrition the risk may be increased.



Regular monthly blood counts are advisable when Septrin is given for long periods, or to folate deficient patients or to the elderly; since there exists a possibility of asymptomatic changes in haematological laboratory indices due to lack of available folate. These changes may be reversed by administration of folinic acid (5 to 10 mg/day) without interfering with the antibacterial activity.



In glucose-6-phosphate dehydrogenase (G-6-PD) deficient patients haemolysis may occur.



Septrin should be given with caution to patients with severe allergy or bronchial asthma.



Septrin should not be used in the treatment of streptococcal pharyngitis due to Group A beta-haemolytic streptococci; eradication of these organisms from the oropharynx is less effective than with penicillin.



Trimethoprim has been noted to impair phenylalanine metabolism but this is of no significance in phenylketonuric patients on appropriate dietary restriction.



The administration of Septrin to patients known or suspected to be at risk of acute porphyria should be avoided. Both trimethoprim and sulphonamides (although not specifically sulfamethoxazole) have been associated with clinical exacerbation of porphyria.



Close monitoring of serum potassium is warranted in patients at risk of hyperkalaemia.



Except under careful supervision Septrin should not be given to patients with serious haematological disorders (see 4.8 Undesirable Effects). Septrin has been given to patients receiving cytotoxic therapy with little or no additional effect on the bone marrow or peripheral blood.



The combination of antibiotics in Septrin should only be used where, in the judgement of the physician, the benefits of treatment outweigh any possible risks; consideration should be given to the use of a single effective antibacterial agent.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Trimethoprim may interfere with the estimation of serum/plasma creatinine when the alkaline picrate reaction is used. This may result in overestimation of serum/plasma creatinine of the order of 10%. The creatinine clearance is reduced: the renal tubular secretion of creatinine is decreased from 23% to 9% whilst the glomerular filtration remains unchanged.



In some situations, concomitant treatment with zidovudine may increase the risk of haematological adverse reactions to co-trimoxazole. If concomitant treatment is necessary, consideration should be given to monitoring of haematological parameters.



Reversible deterioration in renal function has been observed in patients treated with co-trimoxazole and cyclosporin following renal transplantation.



Concurrent use of rifampicin and Septrin results in a shortening of the plasma half-life of trimethoprim after a period of about one week. This is not thought to be of clinical significance.



When trimethoprim is administered simultaneously with drugs that form cations at physiological pH, and are also partly excreted by active renal secretion (e.g. procainamide, amantadine), there is the possibility of competitive inhibition of this process which may lead to an increase in plasma concentration of one or both of the drugs.



In elderly patients concurrently receiving diuretics, mainly thiazides, there appears to be an increased risk of thrombocytopenia with or without purpura.



Occasional reports suggest that patients receiving pyrimethamine at doses in excess of 25 mg weekly may develop megaloblastic anaemia should co-trimoxazole be prescribed concurrently.



Co-trimoxazole has been shown to potentiate the anticoagulant activity of warfarin via stereo-selective inhibition of its metabolism. Sulfamethoxazole may displace warfarin from plasma-albumin protein-binding sites in vitro. Careful control of the anticoagulant therapy during treatment with Septrin is advisable.



Co-trimoxazole prolongs the half-life of phenytoin and if co-administered could result in excessive phenytoin effect. Close monitoring of the patient's condition and serum phenytoin levels are advisable.



Concomitant use of trimethoprim with digoxin has been shown to increase plasma digoxin levels in a proportion of elderly patients.



Co-trimoxazole may increase the free plasma levels of methotrexate.



Trimethoprim interferes with assays for serum methotrexate when dihydrofolate reductase from Lactobacillus casei is used in the assay. No interference occurs if methotrexate is measured by radioimmuno assay.



Administration of trimethoprim/sulfamethoxazole 160mg/800mg (co-trimoxazole) causes a 40% increase in lamivudine exposure because of the trimethoprim component. Lamivudine has no effect on the pharmacokinetics of trimethoprim or sulfamethoxazole.



Interaction with sulphonylurea hypoglycaemic agents is uncommon but potentiation has been reported.



Caution should be exercised in patients taking any other drugs that can cause hyperkalaemia.



If Septrin is considered appropriate therapy in patients receiving other anti-folate drugs such as methotrexate, a folate supplement should be considered.



4.6 Pregnancy And Lactation



Pregnancy



There are not any adequate data from the use of Septrin in pregnant women. Case-control studies have shown that there may be an association between exposure to folate antagonists and birth defects in humans.



Trimethoprim is a folate antagonist and, in animal studies, both agents have been shown to cause foetal abnormalities (see 5.3 Preclinical Safety Data).



Septrin should not be used in pregnancy, particularly in the first trimester, unless clearly necessary. Folate supplementation should be considered if Septrin is used in pregnancy.



Sulfamethoxazole competes with bilirubin for binding to plasma albumin. As significantly maternally derived drug levels persist for several days in the newborn, there may be a risk of precipitating or exacerbating neonatal hyperbilirubinaemia, with an associated theoretical risk of kernicterus, when Septrin is administered to the mother near the time of delivery. This theoretical risk is particularly relevant in infants at increased risk of hyperbilirubinaemia, such as those who are preterm and those with glucose-6-phosphate dehydrogenase deficiency.



Lactation



The components of Septrin (trimethoprim and sulfamethoxazole) are excreted in breast milk. Administration of Septrin should be avoided in late pregnancy and in lactating mothers where the mother or infant has, or is at particular risk of developing, hyperbilirubinaemia. Additionally, administration of Septrin should be avoided in infants younger than eight weeks in view of the predisposition of young infants to hyperbilirubinaemia.



4.7 Effects On Ability To Drive And Use Machines



There have been no studies to investigate the effect of Septrin on driving performance or the ability to operate machinery. Further a detrimental effect on such activities cannot be predicted from the pharmacology of the drug. Nevertheless the clinical status of the patient and the adverse events profile of Septrin should be borne in mind when considering the patients ability to operate machinery.



4.8 Undesirable Effects



The frequency categories associated with the adverse events below are estimates. For most events, suitable data for estimating incidence were not available. In addition, adverse events may vary in their incidence depending on the indication.



Data from large published clinical trials were used to determine the frequency of very common to rare adverse events. Very rare adverse events were primarily determined from post-marketing experience data and therefore refer to reporting rate rather than a "true" frequency.



The following convention has been used for the classification of adverse events in terms of frequency:- Very common



Infections and Infestations






Common:




Monilial overgrowth



Blood and lymphatic system disorders






Very rare:




Leucopenia, neutropenia, thrombocytopenia, agranulocytosis, megaloblastic anaemia, aplastic anaemia, haemolytic anaemia, methaemoglobinaemia, eosinophilia, purpura, haemolysis in certain susceptible G-6-PD deficient patients



The majority of haematological changes are mild and reversible when treatment is stopped. Most of the changes cause no clinical symptoms although they may become severe in isolated cases, especially in the elderly, in those with hepatic or renal dysfunction or in those with poor folate status. Fatalities have been recorded in at-risk patients and these patients should be observed carefully (see 4.3 Contra-indications).



Immune system disorders






Very rare:




Serum sickness, anaphylaxis, allergic myocarditis, angioedema, drug fever, allergic vasculitis resembling Henoch-Schoenlein purpura, periarteritis nodosa, systemic lupus erythematosus



Metabolism and nutrition disorders








Very common:




Hyperkalaemia




Very rare:




Hypoglycaemia, hyponatraemia, anorexia



Close supervision is recommended when co-trimoxazole is used in elderly patients or in patients taking high doses of co-trimoxazole as these patients may be more susceptible to hyperkalaemia and hyponatraemia.



Psychiatric disorders






Very rare:




Depression, hallucinations



Nervous system disorders








Common:




Headache




Very rare:




Aseptic meningitis, convulsions, peripheral neuritis, ataxia, vertigo, tinnitus, dizziness



Aseptic meningitis was rapidly reversible on withdrawal of the drug, but recurred in a number of cases on re-exposure to either co-trimoxazole or to trimethoprim alone.



Respiratory, thoracic and mediastinal disorders






Very rare:




Cough, shortness of breath, pulmonary infiltrates



Cough, shortness of breath and pulmonary infiltrates may be early indicators of respiratory hypersensitivity which, while very rare, has been fatal.



Gastrointestinal disorders










Common:




Nausea, diarrhoea




Uncommon:




Vomiting




Very rare:




Glossitis, stomatitis, pseudomembranous colitis, pancreatitis



Eye Disorders






Very rare:




Uveitis



Hepatobiliary disorders






Very rare:




Elevation of serum transaminases, elevation of bilirubin levels, cholestatic jaundice, hepatic necrosis



Cholestatic jaundice and hepatic necrosis may be fatal.



Skin and subcutaneous tissue disorders








Common:




Skin rashes




Very rare:




Photosensitivity, exfoliative dermatitis, fixed drug eruption, erythema multiforme, Stevens-Johnson syndrome, Lyell's syndrome (toxic epidermal necrolysis)



Lyell's syndrome carries a high mortality.



Musculoskeletal and connective tissue disorders






Very rare:




Arthralgia, myalgia



Renal and urinary disorders






Very rare:




Impaired renal function (sometimes reported as renal failure), interstitial nephritis



Effects associated with Pneumocystis jiroveci (P.carinii) Pneumonitis (PCP) management






Very rare:




Severe hypersensitivity reactions, rash, fever, neutropenia, thrombocytopenia, raised liver enzymes, hyperkalaemia, hyponatraemia



At the high dosages used for PCP management severe hypersensitivity reactions have been reported, necessitating cessation of therapy. If signs of bone marrow depression occur, the patient should be given calcium folinate supplementation (5-10 mg/day). Severe hypersensitivity reactions have been reported in PCP patients on re-exposure to co-trimoxazole, sometimes after a dosage interval of a few days.



4.9 Overdose



Nausea, vomiting, dizziness and confusion are likely signs/symptoms of overdosage. Bone marrow depression has been reported in acute trimethoprim overdosage.



If vomiting has not occurred, induction of vomiting may be desirable. Gastric lavage may be useful, though absorption from the gastrointestinal tract is normally very rapid and complete within approximately two hours. This may not be the case in gross overdosage. Dependant on the status of renal function administration of fluids is recommended if urine output is low.



Both trimethoprim and active sulfamethoxazole are moderately dialysable by haemodialysis. Peritoneal dialysis is not effective.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Combinations of sulfonamides and trimethoprim, incl. derivatives; ATC code: J01EE01



Mode of Action



Septrin is an antibacterial drug composed of two active principles, sulfamethoxazole and trimethoprim. Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthetase enzyme. Sulfamethoxazole competitively inhibits the utilisation of para-aminobenzoic acid (PABA) in the synthesis of dihydrofolate by the bacterial cell resulting in bacteriostasis. Trimethoprim binds to and reversibly inhibits bacterial dihydrofolate reductase (DHFR) and blocks the production of tetrahydrofolate. Depending on the conditions the effect may be bactericidal. Thus trimethoprim and sulfamethoxazole block two consecutive steps in the biosynthesis of purines and therefore nucleic acids essential to many bacteria. This action produces marked potentiation of activity in vitro between the two agents.



Mechanism of resistance



In vitro studies have shown that bacterial resistance can develop more slowly with both sulfamethoxazole and trimethoprim in combination that with either sulfamethoxazole or trimethoprim alone.



Resistance to sulfamethoxazole may occur by different mechanisms. Bacterial mutations cause an increase the concentration of PABA and thereby out-compete with sulfamethoxazole resulting in a reduction of the inhibitory effect on dihydropteroate synthetase enzyme. Another resistance mechanism is plasmid-mediated and results from production of an altered dihydropteroate synthetase enzyme, with reduced affinity for sulfamethoxazole compared to the wild-type enzyme.



Resistance to trimethoprim occurs through a plasmid-mediated mutation which results in production of an altered dihydrofolate reductase enzyme having a reduced affinity for trimethoprim compared to the wild-type enzyme.



Trimethoprim binds to plasmodial DHFR but less tightly than to bacterial enzyme. Its affinity for mammalian DHFR is some 50,000 times less than for the corresponding bacterial enzyme.



Many common pathogenic bacteria are susceptible in vitro to trimethoprim and sulfamethoxazole at concentrations well below those reached in blood, tissue fluids and urine after the administration of recommended doses. In common with other antibiotics, however, in vitro activity does not necessarily imply that clinical efficacy has been demonstrated and it must be noted that satisfactory susceptibility testing is achieved only with recommended media free from inhibitory substances, especially thymidine and thymine.



Breakpoints



EUCAST



Enterobacteriaceae: S



S. maltophilia: S



Acinetobacter: S



Staphylococcus: S



Enterococcus: S



Streptococcus ABCG: S



Streptococcus pneumoniae: S



Hemophilus influenza: S



Moraxella catarrhalis: S



Psuedomonas aeruginosa and other non-enterobacteriaceae: S



S = susceptible, R = resistant. *These are CLSI breakpoints since no EUCAST breakpoints are currently available for these organisms.



Trimethoprim: sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as trimethoprim concentration.



Antibacterial Spectrum



The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. This information gives only an approximate guidance on probabilities whether microorganisms will be susceptible to trimethoprim/sulfamethoxazole or not.



Trimethoprim/sulfamethoxazole susceptibility against a number of bacteria are shown in the table below:












Commonly susceptible species:




Gram-positive aerobes:



Staphylococcus aureus



Staphylococcus saprophyticus



Streptococcus pyogenes




Gram-negative aerobes:



Enterobacter cloacae



Haemophilus influenzae



Klebsiella oxytoca



Moraxella catarrhalis



Salmonella spp.



Stenotrophomonas maltophilia



Yersinia spp.




Species for which acquired resistance may be a problem:




Gram-positive aerobes:



Enterococcus faecalis



Enterococcus faecium



Nocardia spp.



Staphylococcus epidermidis



Streptococcus pneumoniae




Gram-negative aerobes:



Citrobacter spp.



Enterobacter aerogenes



Escherichia coli



Klebsiella pneumoniae



Klebsiella pneumonia



Proteus mirabilis



Proteus vulgaris



Providencia spp.



Serratia marcesans




Inherently resistant organisms:




Gram-negative aerobes:



Pseudomonas aeruginosa



Shigella spp.



Vibrio cholera



5.2 Pharmacokinetic Properties



After oral administration trimethoprim and sulfamethoxazole are rapidly and nearly completely absorbed. The presence of food does not appear to delay absorption. Peak levels in the blood occur between one and four hours after ingestion and the level attained is dose related. Effective levels persist in the blood for up to 24 hours after a therapeutic dose. Steady state levels in adults are reached after dosing for 2-3 days. Neither component has an appreciable effect on the concentrations achieved in the blood by the other.



Trimethoprim is a weak base with a pKa of 7.4. It is lipophilic. Tissue levels of trimethoprim are generally higher than corresponding plasma levels, the lungs and kidneys showing especially high concentrations. Trimethoprim concentrations exceed those in plasma in the case of bile, prostatic fluid and tissue, saliva, sputum and vaginal secretions. Levels in the aqueous humor, breast milk, cerebrospinal fluid, middle ear fluid, synovial fluid and tissue (intestinal) fluid are adequate for antibacterial activity. Trimethoprim passes into amniotic fluid and foetal tissues reaching concentrations approximating those of maternal serum.



Approximately 50% of trimethoprim in the plasma is protein bound. The half-life in man is in the range 8.6 to 17 hours in the presence of normal renal function. It is increased by a factor of 1.5 to 3.0 when the creatinine clearance is less than 10 ml/minute. There appears to be no significant difference in the elderly compared with young patients.



The principal route of excretion of trimethoprim is renal and approximately 50% of the dose is excreted in the urine within 24 hours as unchanged drug. Several metabolites have been identified in the urine. Urinary concentrations of trimethoprim vary widely.



Sulfamethoxazole is a weak acid with a pKa of 6.0. The concentration of active sulfamethoxazole in a variety of body fluids is of the order of 20 to 50% of the plasma concentration.



Approximately 66% of sulfamethoxazole in the plasma is protein bound . The half-life in man is approximately 9 to 11 hours in the presence of normal renal function. There is no change in the half-life of active sulfamethoxazole with a reduction in renal function but there is prolongation of the half-life of the major, acetylated metabolite when the creatinine clearance is below 25 ml/minute.



The principal route of excretion of sulfamethoxazole is renal; between 15% and 30% of the dose recovered in the urine is in the active form. In elderly patients there is a reduced renal clearance of sulphamethoxazole.



5.3 Preclinical Safety Data



Reproductive toxicology:



At doses in excess of recommended human therapeutic dose, trimethoprim and sulfamethoxazole have been reported to cause cleft palate and other foetal abnormalities in rats, findings typical of a folate antagonist. Effects with trimethoprim were preventable by administration of dietary folate. In rabbits, foetal loss was seen at doses of trimethoprim in excess of human therapeutic doses.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Tablets



Sodium starch glycollate



Povidone



*Dioctyl sodium sulphosuccinate



*Docusate sodium



Magnesium stearate



*alternative ingredients



6.2 Incompatibilities



See drug interactions.



6.3 Shelf Life



5 years.



6.4 Special Precautions For Storage



Do not store above 25°C. Keep container in the outer carton.



6.5 Nature And Contents Of Container



Amber glass bottles with low density polyethylene snap-fit closures and PVC/Al foil blister pack.



Pack size: 50 and 100



Round enamelled tins with lever lids.



Pack size: 5000



6.6 Special Precautions For Disposal And Other Handling



Trimethoprim interferes with assays for serum methotrexate when dihydrofolate reductase from Lactobacillus casei is used in the assay. No interference occurs if methotrexate is measured by radioimmuno assay.



Trimethoprim may interfere with the estimation of serum/plasma creatinine when the alkaline picrate reaction is used. This may result in overestimation of serum/plasma creatinine of the order of 10%. Functional inhibition of the renal tubular secretion of creatinine may product a spurious fall in the estimated rate of creatinine clearance.



Administrative Data


7. Marketing Authorisation Holder



Laboratoires GENOPHARM



ZI de l'Esplanade



2, rue Niels Bohr



F – 77400 Saint-Thibault-des-Vignes



8. Marketing Authorisation Number(S)



PL 26946/0006



9. Date Of First Authorisation/Renewal Of The Authorisation



26 January 2002



10. Date Of Revision Of The Text



September 2010




Wednesday, 8 August 2012

Incivek


Pronunciation: tel-A-pre-vir
Generic Name: Telaprevir
Brand Name: Incivek


Incivek is used for:

Treating chronic hepatitis C virus infection in certain patients. It must be used in combination with peginterferon and ribavirin.


Incivek is a hepatitis C virus protease inhibitor. It reduces the amount of hepatitis C virus in the body by preventing the spread of the hepatitis C virus within the body.


Do NOT use Incivek if:


  • you are allergic to any ingredient in Incivek

  • you have moderate to severe liver problems

  • you are taking alfuzosin, certain benzodiazepines (eg, oral midazolam, triazolam), cabazitaxel, cisapride, conivaptan, dronedarone, ergot derivatives (eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine), certain HMG-CoA reductase inhibitors (eg, atorvastatin, lovastatin, simvastatin), lurasidone, pimozide, rifabutin, rifampin, rivaroxaban, silodosin, St. John's wort, or tolvaptan

  • you are taking sildenafil or tadalafil to treat pulmonary arterial hypertension (PAH)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Incivek:


Some medical conditions may interact with Incivek. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have HIV infection; other immune system problems; gout or high blood uric acid levels; or certain blood problems, such as anemia, low blood platelet levels, or low white blood cell levels (neutropenia)

  • if you have other liver problems (eg, hepatitis B infection)

  • if you have had an organ transplant

  • if you will be having surgery

Some MEDICINES MAY INTERACT with Incivek. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Rifabutin, rifampin, or St. John's wort because they may decrease Incivek's effectiveness

  • Alfuzosin, certain benzodiazepines (eg, oral midazolam, triazolam), cabazitaxel, cisapride, conivaptan, dronedarone , ergot derivatives (eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine), certain HMG-CoA reductase inhibitors (eg, atorvastatin, lovastatin, simvastatin), lurasidone, pimozide, rivaroxaban, silodosin, or tolvaptan because the risk of their side effects may be increased by Incivek

  • Sildenafil or tadalafil (when used to treat PAH) because the risk of their side effects may be increased by Incivek

  • Hormonal birth control (eg, birth control pills) because their effectiveness may be decreased by Incivek

  • Many prescription medicines (eg, used for asthma or breathing problems, anxiety, birth control, blood thinning, blood flow, cancer, diabetes, enlarged prostate, erectile dysfunction, gout, angina, heart problems, HIV, immune suppression, infection, inflammation, irregular heartbeat, high blood pressure, high cholesterol, mental or mood problems, pain (eg, narcotics), PAH, seizures, sleep) may interact with Incivek, increasing the risk of side effects or decreasing effectiveness

This may not be a complete list of all interactions that may occur. Ask your health care provider if Incivek may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Incivek:


Use Incivek as directed by your doctor. Check the label on the medicine for exact dosing instructions. Check the label on the medicine for exact dosing instructions.


  • Incivek comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Incivek refilled.

  • Incivek must be taken with peginterferon and ribavirin, which come with their own Medication Guides. Be sure to read those Medication Guides each time you get them filled.

  • Take Incivek by mouth with food (not low fat). Eat a meal or snack that contains about 20 grams of fat within 30 minutes before you take Incivek. Examples of some foods include: a bagel with cream cheese, 1 cup nuts, 3 tablespoons peanut butter, 1 cup ice cream; 2 ounces American or cheddar cheese, 2 ounces potato chips, or 1 cup trail mix.

  • Incivek works best if it is taken at the same time each day. Each dose should be taken 7 to 9 hours apart.

  • Continue to take Incivek even if you feel well. Do not miss any doses.

  • If you miss a dose of Incivek and you remember within 4 hours of when you usually take it, take the missed dose with food as soon as possible and go back to your regular dosing schedule. If you miss a dose of Incivek and it is more than 4 hours after the time you usually take it, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Incivek.



Important safety information:


  • Mild skin rashes are common with the use of Incivek. Sometimes these skin rashes and other skin reactions can become severe. Contact your doctor right away if you develop a rash with or without itching; fever; mouth sores or ulcers; red or irritated eyes; red, swollen, blistered, or peeling skin; or swelling of the face.

  • Incivek may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.

  • Incivek may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.

  • Incivek does not stop you from spreading hepatitis C virus to others through sexual contact, sharing needles, or being exposed to your blood. Use barrier methods of birth control (eg, condoms) if you have hepatitis C virus infection. Talk with your doctor about safe sexual practices that protect your partner. Never share needles or other injection supplies. Do not share personal items that may have blood or body fluids on them, like toothbrushes or razors.

  • Do not change your dose without checking with your doctor.

  • Incivek is not a cure for hepatitis C virus infection. Remain under the care of your doctor.

  • When your medicine supply is low, get more from your doctor or pharmacist as soon as you can. Do not stop taking Incivek, even for a short period of time. If you do, the virus may grow resistant to the medicine and become harder to treat.

  • Women who may become pregnant and men who use Incivek must use 2 effective forms of birth control while they take Incivek with ribavirin and for 6 months after treatment is stopped. Hormonal birth control (eg, birth control pills) may not be as effective while you are using Incivek and for up to 2 weeks after stopping Incivek. Talk with your doctor if you have questions about effective birth control.

  • Lab tests, including complete blood cell counts, electrolyte levels, liver and kidney function, hepatitis C virus antibody levels, thyroid function, and uric acid levels, may be performed while you use Incivek and for several months after you stop Incivek. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Incivek with caution in the ELDERLY; they may be more sensitive to its effects.

  • Incivek should be used with extreme caution in CHILDREN younger than 18 years; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: Incivek must be used with ribavirin. Ribavirin use during pregnancy has resulted in birth defects and fetal death. If you are able to become pregnant, talk with your doctor or pharmacist about the use of effective birth control while using Incivek. If you become pregnant, contact your doctor immediately. You will need to discuss the benefits and risks of using Incivek while you are pregnant. It is not known if Incivek is found in breast milk. Do not breast-feed while taking Incivek.


Possible side effects of Incivek:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Anal or rectal problems (eg, burning, discomfort, itching, hemorrhoids); change in taste; diarrhea; nausea; tiredness; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); change in the amount of urine produced; dark, tarry, or bloody stools; dizziness; fast or irregular heartbeat; feeling cold, especially in the hands or feet; fever, chills, or sore throat; joint pain (especially in the big toe); mouth sores or ulcers; pale skin; rash (with or without itching); red or irritated eyes; red, swollen, blistered, or peeling skin; severe or prolonged nausea or vomiting; shortness of breath; swelling of the face; unusual tiredness or weakness; yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Incivek side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms include change in taste; decreased appetite; diarrhea; headache; nausea; vomiting.


Proper storage of Incivek:

Store Incivek at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Once the bottle is opened, use within 28 days. Keep Incivek out of the reach of children and away from pets.


General information:


  • If you have any questions about Incivek, please talk with your doctor, pharmacist, or other health care provider.

  • Incivek is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Incivek. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Incivek resources


  • Incivek Side Effects (in more detail)
  • Incivek Use in Pregnancy & Breastfeeding
  • Incivek Drug Interactions
  • Incivek Support Group
  • 1 Review for Incivek - Add your own review/rating


  • Incivek Prescribing Information (FDA)

  • Incivek Advanced Consumer (Micromedex) - Includes Dosage Information

  • Incivek Consumer Overview

  • Telaprevir Professional Patient Advice (Wolters Kluwer)



Compare Incivek with other medications


  • Hepatitis C